• Regeneron Pharmaceuticals, Inc.

    The Japanese Ministry of Health, Labour and Welfare has approved Eylea (aflibercept) for diabetic macular edema.

    Eylea has already been approved in Japan for wet AMD, macular edema secondary to central retinal vein occlusion and myopic choroidal neovascularization. A marketing authorization application has been submitted in Japan for the treatment of macular edema secondary to branch retinal vein occlusion.

    Eylea is approved in the United States for wet AMD, diabetic macular edema and macular edema following retinal vein occlusion.